AR106494A1 - Uso terapéutico de una solución oftálmica acuosa estéril, método de tratamiento - Google Patents
Uso terapéutico de una solución oftálmica acuosa estéril, método de tratamientoInfo
- Publication number
- AR106494A1 AR106494A1 ARP160103302A ARP160103302A AR106494A1 AR 106494 A1 AR106494 A1 AR 106494A1 AR P160103302 A ARP160103302 A AR P160103302A AR P160103302 A ARP160103302 A AR P160103302A AR 106494 A1 AR106494 A1 AR 106494A1
- Authority
- AR
- Argentina
- Prior art keywords
- ophthalmic solution
- acetylcysteinyl
- chitosan
- solution
- pharmaceutically acceptable
- Prior art date
Links
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 5
- 239000002997 ophthalmic solution Substances 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 5
- 229920001661 Chitosan Polymers 0.000 abstract 4
- -1 N-acetylcysteinyl Chemical group 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- 235000011149 sulphuric acid Nutrition 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una solución oftálmica acuosa estéril que comprende N-(N-acetilcisteinil)quitosano o una de sus sales farmacéuticamente aceptables en una solución portadora, en donde el N-(N-acetilcisteinil)quitosano tiene un contenido de grupos tiol libres en una cantidad de 80 mmol/g de polímero a 280 mmol/g de polímero, para usar en el tratamiento de heridas de la córnea. Reivindicación 5: Solución oftálmica para usar de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque la concentración del N-(N-acetilcisteinil)quitosano o dicha sal farmacéuticamente aceptable en dicha solución es del 0,05 al 0,3% (p/p), con preferencia, del 0,05 al 0,2% (p/p), con mayor preferencia, 0,08 0,16% (p/p). Reivindicación 6: Solución oftálmica para usar de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque dicha sal farmacéuticamente aceptable se selecciona del grupo que consiste en sales de ácidos orgánicos tales como ácido acético, cítrico, fórmico y tartárico y sales de ácidos minerales tales como HCl y H₂SO₄. Reivindicación 8: Solución oftálmica para usar de acuerdo con cualquiera de; las reivindicaciones precedentes, caracterizada porque la cantidad de grupos tiol reticulados en el N-(N-acetilcisteinil)quitosano es del 30% o menos de los grupos tiol totales dentro, con preferencia, del 25% o menos, con máxima preferencia; 15% o menos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15192362 | 2015-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106494A1 true AR106494A1 (es) | 2018-01-17 |
Family
ID=54476731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103302A AR106494A1 (es) | 2015-10-30 | 2016-10-28 | Uso terapéutico de una solución oftálmica acuosa estéril, método de tratamiento |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10583152B2 (es) |
| EP (1) | EP3368007B1 (es) |
| JP (1) | JP6817300B2 (es) |
| KR (1) | KR20180066104A (es) |
| CN (1) | CN108348455B (es) |
| AR (1) | AR106494A1 (es) |
| BR (1) | BR112018007686A2 (es) |
| CA (1) | CA3001634C (es) |
| ES (1) | ES2796361T3 (es) |
| IL (1) | IL258785B (es) |
| MX (1) | MX380088B (es) |
| PL (1) | PL3368007T3 (es) |
| PT (1) | PT3368007T (es) |
| RU (1) | RU2741912C2 (es) |
| WO (1) | WO2017072236A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018202783A1 (en) | 2017-05-03 | 2018-11-08 | Croma-Pharma Gmbh | Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders |
| CN113318075B (zh) * | 2021-06-24 | 2022-09-13 | 四川普锐特药业有限公司 | 一种乙酰半胱氨酸溶液及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| FR2692582B1 (fr) | 1992-06-18 | 1998-09-18 | Flamel Tech Sa | Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux. |
| AT406054B (de) | 1998-11-04 | 2000-02-25 | Andreas Bernkop-Schnuerch | Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung |
| GB2386900B (en) | 2002-03-25 | 2006-11-01 | Johnson & Johnson Medical Ltd | Use in wound dressings of chemically modified polysaccharides |
| US9597277B2 (en) | 2006-12-22 | 2017-03-21 | Croma-Pharma Gesellschaft M.B.H. | Use of polymers |
| EP2114370B1 (en) | 2007-01-31 | 2012-10-03 | Allergan, Inc. | Novel biomaterials for ocular drug delivery and a method for making and using same |
| US9452592B2 (en) | 2007-08-28 | 2016-09-27 | Cryovac, Inc. | Multilayer film having an active oxygen barrier layer with radiation enhanced active barrier properties |
| EP2187835B1 (en) | 2007-08-31 | 2016-10-05 | DENTSPLY International Inc. | Three-dimensional printing methods and materials for making dental products |
| AU2009240511B2 (en) | 2008-04-24 | 2015-01-22 | Medtronic, Inc. | Thiolated chitosan gel |
| JP5757861B2 (ja) | 2008-04-24 | 2015-08-05 | メドトロニック，インコーポレイテッド | キトサン−含有保護用組成物 |
| JP5833919B2 (ja) | 2008-04-24 | 2015-12-16 | メドトロニック，インコーポレイテッド | キトサンと酸化多糖とに基づく保護用ゲル |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US9439925B2 (en) * | 2010-04-06 | 2016-09-13 | Synedgen, Inc. | Methods and compositions for treating wounds utilizing chitosan compounds |
| ITMI20120847A1 (it) * | 2012-05-16 | 2013-11-17 | Labomar S R L | Formulazione per sostanze a bassa biodisponibilità. |
| AU2015257874B2 (en) | 2014-05-07 | 2019-11-28 | Croma-Pharma Gesellschaft M.B.H. | Aqueous ophthalmic solution and method for treating dry eye syndrome |
-
2016
- 2016-10-27 BR BR112018007686A patent/BR112018007686A2/pt not_active Application Discontinuation
- 2016-10-27 CN CN201680063529.5A patent/CN108348455B/zh active Active
- 2016-10-27 US US15/769,487 patent/US10583152B2/en active Active
- 2016-10-27 IL IL258785A patent/IL258785B/en unknown
- 2016-10-27 KR KR1020187010874A patent/KR20180066104A/ko not_active Abandoned
- 2016-10-27 WO PCT/EP2016/075939 patent/WO2017072236A1/en not_active Ceased
- 2016-10-27 JP JP2018521606A patent/JP6817300B2/ja not_active Expired - Fee Related
- 2016-10-27 CA CA3001634A patent/CA3001634C/en active Active
- 2016-10-27 ES ES16787869T patent/ES2796361T3/es active Active
- 2016-10-27 PT PT167878693T patent/PT3368007T/pt unknown
- 2016-10-27 MX MX2018004779A patent/MX380088B/es unknown
- 2016-10-27 RU RU2018119126A patent/RU2741912C2/ru active
- 2016-10-27 PL PL16787869T patent/PL3368007T3/pl unknown
- 2016-10-27 EP EP16787869.3A patent/EP3368007B1/en active Active
- 2016-10-28 AR ARP160103302A patent/AR106494A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018119126A3 (es) | 2020-02-14 |
| KR20180066104A (ko) | 2018-06-18 |
| IL258785A (en) | 2018-06-28 |
| WO2017072236A1 (en) | 2017-05-04 |
| MX2018004779A (es) | 2018-06-19 |
| EP3368007A1 (en) | 2018-09-05 |
| RU2741912C2 (ru) | 2021-01-29 |
| US20180303865A1 (en) | 2018-10-25 |
| BR112018007686A2 (pt) | 2018-11-06 |
| RU2018119126A (ru) | 2019-12-03 |
| CN108348455B (zh) | 2021-04-09 |
| MX380088B (es) | 2025-03-11 |
| EP3368007B1 (en) | 2020-03-18 |
| PT3368007T (pt) | 2020-06-17 |
| CA3001634C (en) | 2023-05-23 |
| CA3001634A1 (en) | 2017-05-04 |
| IL258785B (en) | 2022-08-01 |
| CN108348455A (zh) | 2018-07-31 |
| ES2796361T3 (es) | 2020-11-26 |
| US10583152B2 (en) | 2020-03-10 |
| JP6817300B2 (ja) | 2021-01-20 |
| PL3368007T3 (pl) | 2020-11-02 |
| JP2018535962A (ja) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377727B (es) | Solución oftálmica acuosa y método para tratar el síndrome del ojo seco. | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| MX2019005300A (es) | Polimeros enlazados al proton para administracion oral. | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| AR106494A1 (es) | Uso terapéutico de una solución oftálmica acuosa estéril, método de tratamiento | |
| MX2015012716A (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. | |
| BR112017011513A2 (pt) | tratamento de condições oculares usando células progenitoras | |
| AR102562A1 (es) | Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| RU2015115143A (ru) | Ранозаживляющий гель для наружного применения | |
| BR102018006534A8 (pt) | Métodos para melhorar a atividade dos retinoides | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| AR106493A1 (es) | Uso terapéutico de una solución oftálmica acuosa estéril | |
| EA201991530A1 (ru) | Композиции и способы лечения биопленок | |
| UA112033U (uk) | Спосіб лікування ускладненої варикозної хвороби нижніх кінцівок | |
| RU2014148877A (ru) | Способы воздействия на экспрессию гена BRCA1 | |
| RU2013100450A (ru) | Способ лечения желчнокаменной болезни в эксперименте | |
| RU2014145911A (ru) | Способы воздействия на экспрессию гена BRCA2 | |
| RU2014145910A (ru) | Способы воздействия на экспрессию гена APOE | |
| RU2014142758A (ru) | Способ воздействия на экспрессию гена серповидной анемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |